![Benjamin Kelmendi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Benjamin Kelmendi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Transcend Therapeutics
![]() Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Gründer | - | - |
Corporate Officer/Principal | - | - |
Karriereverlauf von Benjamin Kelmendi
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Founder | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Transcend Therapeutics
![]() Transcend Therapeutics BiotechnologyHealth Technology Transcend Therapeutics is an American biotechnology company that discovers, develops, and delivers next-generation psychoactive medicines to work towards a world where people no longer suffer from neuropsychiatric disease. The company is located in the US. The company focuses on developing medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. Transcend Therapeutics has real-world data for its lead compound, TSND-201, demonstrating robust responses in patients with PTSD. As a public benefit corporation, the company has pledged 10% of its founding shares towards nonprofits focused on scientific research and patient access. | Health Technology |
- Börse
- Insiders
- Benjamin Kelmendi
- Erfahrung